These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 30214012

  • 1. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
    Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, Macraild S, Zhang L, Teh TC, Tiong IS, Lan P, Chanrion M, Claperon A, Rocchetti F, Zichi A, Kraus-Berthier L, Wang Y, Halilovic E, Morris E, Colland F, Segal D, Huang D, Roberts AW, Maragno AL, Lessene G, Geneste O, Wei AH.
    Leukemia; 2019 Apr; 33(4):905-917. PubMed ID: 30214012
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS, Bilardi RA, Ng AP, Xu Z, Robati M, Vandenberg CJ, Cory S.
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [Abstract] [Full Text] [Related]

  • 4. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
    Ewald L, Dittmann J, Vogler M, Fulda S.
    Cell Death Dis; 2019 Dec 04; 10(12):917. PubMed ID: 31801941
    [Abstract] [Full Text] [Related]

  • 5. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Thijssen R, Diepstraten ST, Moujalled D, Chew E, Flensburg C, Shi MX, Dengler MA, Litalien V, MacRaild S, Chen M, Anstee NS, Reljić B, Gabriel SS, Djajawi TM, Riffkin CD, Aubrey BJ, Chang C, Tai L, Xu Z, Morley T, Pomilio G, Bruedigam C, Kallies A, Stroud DA, Bajel A, Kluck RM, Lane SW, Schoumacher M, Banquet S, Majewski IJ, Strasser A, Roberts AW, Huang DCS, Brown FC, Kelly GL, Wei AH.
    Blood; 2021 May 20; 137(20):2721-2735. PubMed ID: 33824975
    [Abstract] [Full Text] [Related]

  • 6. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
    Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, Boyd KL, Strickland SA, Sensintaffar J, Hogdal LJ, Ayers GD, Olejniczak ET, Fesik SW, Savona MR.
    Cancer Discov; 2018 Dec 20; 8(12):1566-1581. PubMed ID: 30185627
    [Abstract] [Full Text] [Related]

  • 7. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
    Liu F, Zhao Q, Su Y, Lv J, Gai Y, Liu S, Lin H, Wang Y, Wang G.
    Exp Hematol; 2022 Jan 20; 105():39-49. PubMed ID: 34767916
    [Abstract] [Full Text] [Related]

  • 8. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
    Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, Leutz B, Adamia S, Zhu H, Kuang Y, Mogili A, Louissaint A, Bohl SR, Kim AS, Mehta AK, Sanghavi S, Wang Y, Morris E, Halilovic E, Paweletz CP, Weinstock DM, Garcia JS, Letai A.
    Cancer Cell; 2020 Dec 14; 38(6):872-890.e6. PubMed ID: 33217342
    [Abstract] [Full Text] [Related]

  • 9. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
    Rahmani M, Aust MM, Hawkins E, Parker RE, Ross M, Kmieciak M, Reshko LB, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Grant S.
    Haematologica; 2015 Dec 14; 100(12):1553-63. PubMed ID: 26452980
    [Abstract] [Full Text] [Related]

  • 10. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma.
    Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, Havranek O, Soukup J, Svobodova K, Zemanova Z, Tuskova D, Pokorna E, Helman K, Forsterova K, Pacheco-Blanco M, Vockova P, Berkova A, Fronkova E, Trneny M, Klener P.
    Clin Cancer Res; 2019 Jul 15; 25(14):4455-4465. PubMed ID: 31004002
    [Abstract] [Full Text] [Related]

  • 11. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
    Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, Jabbour A, Cummins K, Lackovic K, Blombery P, Thompson E, Ekert PG, Lessene G, Glaser SP, Huang DCS, Roberts AW, Guthridge MA, Wei AH.
    Leukemia; 2018 Feb 15; 32(2):303-312. PubMed ID: 28751770
    [Abstract] [Full Text] [Related]

  • 12. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
    Huang S, Li C, Zhang X, Pan J, Li F, Lv Y, Huang J, Ling Q, Ye W, Mao S, Huang X, Jin J.
    Mol Oncol; 2020 Oct 15; 14(10):2560-2573. PubMed ID: 32519423
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
    Wang X, Mak PY, Mu H, Tao W, Rao A, Visweswaran R, Ruvolo V, Pachter JA, Weaver DT, Andreeff M, Xu B, Carter BZ.
    Mol Cancer Ther; 2020 Aug 15; 19(8):1636-1648. PubMed ID: 32404407
    [Abstract] [Full Text] [Related]

  • 15. A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma.
    Bierbrauer A, Jacob M, Vogler M, Fulda S.
    Br J Cancer; 2020 May 15; 122(10):1544-1551. PubMed ID: 32203216
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
    Li L, Pongtornpipat P, Tiutan T, Kendrick SL, Park S, Persky DO, Rimsza LM, Puvvada SD, Schatz JH.
    Leukemia; 2015 Aug 15; 29(8):1702-12. PubMed ID: 25882699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.